Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Infection & Immunity
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Impact
        • Technologies
        • Commercialisation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research.

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in memory
        • Advise on our research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Careers
        • Study opportunities
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events.

        • News
        • Statements
        • Events
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges.

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > Researchers shed new light on devastating drug-resistant bacteria

Researchers shed new light on devastating drug-resistant bacteria

Date time 18 February, 2022
News Type News type Media release
Centenary Institute researchers have uncovered new insight into Mycobacterium abscessus, a highly drug-resistant bacteria that can cause serious infection and lung damage in vulnerable people. The bacteria is considered an emerging health threat with infection numbers on the rise globally.

Commonly found in soil, dust and water, Mycobacterium abscessus is closely related to the bacteria that cause tuberculosis and leprosy. Individuals with underlying disorders such as bronchiectasis or cystic fibrosis (an inherited form of lung disease) are particularly susceptible to Mycobacterium abscessus infection.

In the published study that used adult zebrafish as a model, researchers found that the immune system reacted in different ways, dependent on the Mycobacterium abscessus variant in play. The findings are a critical step in developing potential new treatments to fight Mycobacterium abscessus infection.

“Mycobacterium abscessus is emerging as a major threat and is increasing in prevalence within patient groups with respiratory conditions. It attacks lung tissue making it hard to breathe and is notorious for being extremely drug and antibiotic resistant,” said Dr Oehlers, study senior author and researcher affiliated with both the Centenary Institute and A*STAR Infectious Diseases Labs (Singapore).

“There are two types of Mycobacterium abscessus – rough and smooth. The rough variant of the bacterium differs from the smooth in that it lacks certain surface lipids. We wanted to better understand the body’s immune response to both variants.”

Discovered by the researchers was that infection by the rough variant caused a hyperactive immune response in the zebrafish being studied, this driving increased inflammation and tissue destruction. The smooth variant, although proliferating to high levels in the zebrafish, saw reduced levels of inflammation and tissue damage. This outcome mirrored the lower rate of pulmonary (lung) decline often seen in human patients infected with the smooth variant of Mycobacterium abscessus. 

“Our findings are important as studying the immune system and how it reacts to Mycobacterium abscessus is key to developing new therapeutics that can best fight this potentially devastating bacterial infection,” said Dr Oehlers.

Dr Oehlers said that medical research in the area was challenging as previous Mycobacterium abscessus models had not been able to convincingly recreate human disease conditions.

“Our new zebrafish model will allow researchers to further dig into the genetic and environmental factors that cause some people to get severe infection while others are able to clear Mycobacterium abscessus from their body without symptoms.”

The study was published in the journal Nature Communications.

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Researchers shed new light on devastating drug-resistant bacteria

Download

Recent Stories

  • New grant targets longer-lasting islet cell treatments for type 1 diabetes

    Dr Lise Hunault, a researcher in the Centenary Institute’s Centre for Biomedical AI, has been awarded a major research grant from Breakthrough T1D, the leading global type 1 diabetes research and advocacy organisation, to advance islet-cell replacement therapies for type 1 diabetes.
    News Type: Research News
    Date 16 Mar 2026
  • Centenary marks International Women’s Day with inspiring speakers

    The Centenary Institute community came together to celebrate International Women’s Day 2026, with a special event highlighting this year’s Australian theme, ‘Balancing the Scales.’
    News Type: Community
    Date 11 Mar 2026
  • Vaxosome launched to develop next-generation mRNA vaccines

    A new biotechnology company, Vaxosome, has been launched to develop next-generation vaccines aimed at tackling some of the world’s most challenging infectious diseases.
    News Type: Research News
    Date 10 Mar 2026
  • Centenary partners in transformative national liver health program

    The Snow Medical Research Foundation has today announced major long-term funding of $15.5 million for a new national research program targeting fatty liver disease, a condition that affects up to one in three Australians. The Centenary Institute will play a key role in the collaborative effort.
    News Type: Research News
    Date 05 Mar 2026

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About us
  • Governance
  • Corporate information

Research

  • Our researchers
  • News

Careers & studies

  • Career opportunities
  • Student opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement
  • Staff Intranet

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram